New
US$ 25.93
glp 1 receptor agonists contraindications Adverse Effects of GLP-1 contraindications to glp 1 Independent
Description
Patients considering GLP-1 therapy should understand that any joint pain improvement is likely a secondary benefit rather than a primary therapeutic target
PMID: 25994567
But losing more than 1.5%2% of body weight per week raises the risk of muscle and bone loss
Both Ozempic and Trulicity belong to the GLP-1 receptor agonist drug class
The analogs of 7 created in this manner were tested for DPP-8 and DPP-9 activity, as well as for activity against DPP-4 and DPP-2
